CD274 and neoplasm: In an exploratory analysis of CheckMate 026 that compared first‐line nivolumab with chemotherapy in patients with PD‐L1‐positive NSCLC, patients with a high tumor mutation burden had a higher response rate with nivolumab than with chemotherapy 29.